Navigation Links
VisEn Launches Next-Generation Fast ('Fluorescence Activatible Sensor Technology') Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
Date:4/20/2009

MMPSense(TM) 750 FAST is Presented at AACR 100th Annual Meeting

BEDFORD, Mass., April 20 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the introduction of its new FAST ("Fluorescent Activatible Sensor Technology") imaging agent platform for advanced imaging of key disease-associated biomarkers and drug response in vivo. Newly developed by VisEn Medical, FAST imaging agents are smaller molecule, biocompatible, activatible fluorescent agents that combine increased biomarker specificity with accelerated pharmacokinetics for advanced measurement and monitoring of key disease biomarkers in vivo. The new MMPSense 750 FAST, the first of the FAST agents to be launched by VisEn, was described today in a scientific poster presentation entitled "In vivo imaging of treatment effects using a novel near-infrared labeled agent: MMPSense 750 FAST", at the annual Scientific Sessions of the AACR (American Association of Cancer Research) 100th Annual Meeting 2009 in Denver, CO by Jeffrey D. Peterson, Ph.D., Vice President of Applied Biology at VisEn.

At the AACR 100th Annual Meeting, the Peterson et al study demonstrated the performance of MMPSense 750 FAST as a fast-acting, near-infrared imaging agent to measure tumor MMP activity in vivo and monitor treatment efficacy. In the study, administration of the agent allowed the non-invasive measurement of MMP inhibition using two different chemotherapy regimes. Using the VisEn FMT 2500(TM) quantitative tomography system, tumor fluorescence due to in vivo activation of the agent was clearly detectable as early as 4 hours after injection of the agent with the signal maximizing between 6 and 24 hours. By 96 hours, only 15% of the signal was still present in tumors. "Our study utilized MMPSense 750 FAST as a mechani
'/>"/>

SOURCE VisEn Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
2. VisEn Medical Raises $7 Million in Series B Financing
3. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
4. Cell Biosciences Launches Next-Generation Protein Characterization System
5. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
6. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
7. US Oncology Launches New Web Site
8. Pharmaceutical Institute Launches New Training Series Focused on Managed Markets Excellence
9. Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada
10. Selexis Launches Biosimilar Cell Line Development Program
11. First Application to Fight High Cholesterol Launches on the iPhone and iPod Touch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... pet owners drew up their lists of New Year,s resolutions for ... of my furry companion." Nowadays there are pet salons, dog and ... take the little canine or feline darlings along wherever mommy or ... pricey toys at the pet store. But anyone who has ever ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest ... research medicinal plants and therapeutic derivatives thereof has ... professionals, and researchers about the challenges of adulterated ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society for ...
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... N.Y. Jie Lian, assistant professor in the Department ... Institute, has won a prestigious Faculty Early Career Development ... Lian will use the five-year, $500,000 award to further ... in nuclear energy systems. The CAREER Award is given ...
... ("Oxford"), a specialty finance firm that provides senior debt ... a $15 million round of debt financing for NanoString ... to NanoString from both Oxford and Silicon Valley Bank, ... a $2 million revolving line of credit.  Proceeds of ...
... N.J., April 3, 2012 Laureate Biopharmaceutical Services, Inc. ... announced the appointment of James D. Utterback to the ... ) "Jim is an invaluable ... have access to his deep industry knowledge," said Michael ...
Cached Biology Technology:Rensselaer professor Jie Lian receives NSF CAREER Award 2Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies 2Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies 3Laureate Biopharma Names James D. Utterback to Board of Directors 2
(Date:4/20/2014)... breast and pancreatic cancers also promote drug-resistance and ultimately ... San Diego School of Medicine have discovered a molecule, ... tumors that appears responsible for inducing tumor metastasis by ... , The findings, published in the April 20, 2014 ... point to new therapeutic opportunities for reversing drug resistance ...
(Date:4/20/2014)... -- Using corn crop residue to make ethanol and ... greenhouse gases than gasoline, according to a study published ... , The findings by a University of Nebraska-Lincoln team ... be used to meet federal mandates to ramp up ... stover -- the stalks, leaves and cobs in cornfields ...
(Date:4/18/2014)... while feeding a world population predicted to reach ... approach to conservation that considers human-altered landscapes such ... and the natural habitat that supports it might ... where at least three-quarters of the land surface ... is vulnerable to human-caused impacts such as climate ...
Breaking Biology News(10 mins):Cancer stem cells linked to drug resistance 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4
... in humans it is detected in approximately 0.5% ... a kidney abnormality known as hydronephrosis. Hydronephrosis arises because ... bladder is impeded. By studying kidney development in mice, ... Children, Toronto, have identified a new cellular mechanism underlying ...
... BOSTON Congenital heart diseases affect approximately one in ... birth defect and the number-one cause of pediatric deaths. ... drug rapamycin can reverse cardiac muscle damage in a mouse ... the first possible medical treatment for this rare condition, but ...
... choices an individual makes about environmental issues are affected ... network. Michigan State University scientists are studying how to ... sustainability science. "Instead of trying to communicate with ... using the structure of social networks to spread information," ...
Cached Biology News:Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome 2Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome 3Sustainability solutions need the power of networks 2